MicroRNA‑155 inhibits the proliferation of CD8+ T�cells via upregulating regulatory T cells in vitiligo
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
It has been reported that loss and degradation of epidermal melanocytes is closely associated with the pathogenesis of vitiligo. In addition, CD8+ T and regulatory T (Treg) cells serve an important role during these two processes. MicroRNA‑155 (miR‑155) is known to contribute to the pathogenesis of vitiligo; however, the mechanism by which miR‑155 regulates the development of vitiligo remains unclear. In the present study, naïve T and CD8+ T cells were isolated from a patient with non‑segmental vitiligo by flow cytometry. The cells were differentiated into Treg cells by treatment with interleukin‑2, transforming growth factor‑β and retinoic acid. In addition, miR‑155 agonists and antagonists were used to investigate the effect of miR‑155 on the proliferation of CD8+ T cells, Treg cells and melanocytes. The results demonstrated that the miR‑155 agonist significantly decreased the rate of CD8+ T cell growth, as well as promoted the proliferation of melanocytes by inducing an increase in the percentage of Treg cells. By contrast, the miR‑155 antagonist inhibited the proliferation of melanocytes by decreasing the percentage of Treg cells. miR‑155 protected melanocyte survival by increasing the number of Treg cells and by decreasing the number of CD8+ T cells. Therefore, these data may provide a new prospect for the treatment of vitiligo.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- MicroRNA‑155 inhibits the proliferation of CD8+ T�cells via upregulating regulatory T cells in vitiligo
- Date Crossref
- 23/08/2019
- Éditeur
- Spandidos Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Qilu Hospital of Shandong University Department of Dermatology pays non établi dans la noticeÉtablissement de santé
-
Wenzhou Medical University Department of Dermatology pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Wenzhou Medical University pays non établi dans la noticeÉtablissement de santé
-
Jinan Central Hospital Department of Dermatology pays non établi dans la noticeÉtablissement de santé
Department of Dermatology — Qilu Hospital of Shandong University, Department of Dermatology — Wenzhou Medical University et First Affiliated Hospital of Wenzhou Medical University, avec 1 autre affiliation.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.